Answers are grounded in this paper and cite their sources.
In mice with liver tumors, injection of LipC6 reduces the number of TAMs and the ability of TAMs to suppress the anti-tumor immune response. LipC6 also increases the anti-tumor effects of TAS CD8⁺ T cells. LipC6 might therefore increase the efficacy of immune therapy in patients with hepatocellular carcinoma.
No takes yet. Share an insight, caveat, or question.
Li et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: